These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1412 related articles for article (PubMed ID: 17980938)

  • 1. Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.
    Pellissier JM; Brisson M; Levin MJ
    Vaccine; 2007 Nov; 25(49):8326-37. PubMed ID: 17980938
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of vaccination of the elderly against herpes zoster in The Netherlands.
    de Boer PT; Pouwels KB; Cox JM; Hak E; Wilschut JC; Postma MJ
    Vaccine; 2013 Feb; 31(9):1276-83. PubMed ID: 23306360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccination: a new option to reduce the burden of herpes zoster.
    Mick G
    Expert Rev Vaccines; 2010 Mar; 9(3 Suppl):31-5. PubMed ID: 20192716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Health economic evaluation of vaccination strategies for the prevention of herpes zoster and postherpetic neuralgia in Germany.
    Ultsch B; Weidemann F; Reinhold T; Siedler A; Krause G; Wichmann O
    BMC Health Serv Res; 2013 Sep; 13():359. PubMed ID: 24070414
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The potential cost-effectiveness of vaccination against herpes zoster and post-herpetic neuralgia.
    Brisson M; Pellissier JM; Camden S; Quach C; De Wals P
    Hum Vaccin; 2008; 4(3):238-45. PubMed ID: 18382137
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Herpes zoster vaccine: A health economic evaluation for Switzerland.
    Blank PR; Ademi Z; Lu X; Szucs TD; Schwenkglenks M
    Hum Vaccin Immunother; 2017 Jul; 13(7):1495-1504. PubMed ID: 28481678
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-Effectiveness of Herpes Zoster Vaccine for Persons Aged 50 Years.
    Le P; Rothberg MB
    Ann Intern Med; 2015 Oct; 163(7):489-97. PubMed ID: 26344036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccination strategies for the prevention of herpes zoster and postherpetic neuralgia.
    Betts RF
    J Am Acad Dermatol; 2007 Dec; 57(6 Suppl):S143-7. PubMed ID: 18021866
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of vaccination against herpes zoster in adults aged over 60 years in Belgium.
    Bilcke J; Marais C; Ogunjimi B; Willem L; Hens N; Beutels P
    Vaccine; 2012 Jan; 30(3):675-84. PubMed ID: 22120193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention of herpes zoster and its painful and debilitating complications.
    Johnson R; McElhaney J; Pedalino B; Levin M
    Int J Infect Dis; 2007 Nov; 11 Suppl 2():S43-8. PubMed ID: 18162246
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of vaccination against herpes zoster and postherpetic neuralgia: a critical review.
    Kawai K; Preaud E; Baron-Papillon F; Largeron N; Acosta CJ
    Vaccine; 2014 Mar; 32(15):1645-53. PubMed ID: 24534737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost effectiveness of herpes zoster vaccine in Canada.
    Najafzadeh M; Marra CA; Galanis E; Patrick DM
    Pharmacoeconomics; 2009; 27(12):991-1004. PubMed ID: 19908924
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.
    Hornberger J; Robertus K
    Ann Intern Med; 2006 Sep; 145(5):317-25. PubMed ID: 16954357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Varicella zoster vaccines.
    Creed R; Satyaprakash A; Ravanfar P
    Dermatol Ther; 2009; 22(2):143-9. PubMed ID: 19335725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel vaccine (Zostavax) to prevent herpes zoster and postherpetic neuralgia.
    Holcomb K; Weinberg JM
    J Drugs Dermatol; 2006 Oct; 5(9):863-6. PubMed ID: 17039651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Health economic evaluation of a vaccine for the prevention of herpes zoster (shingles) and post-herpetic neuralgia in adults in Belgium.
    Annemans L; Bresse X; Gobbo C; Papageorgiou M
    J Med Econ; 2010; 13(3):537-51. PubMed ID: 20707768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of varicella vaccine against herpes zoster and post-herpetic neuralgia for elderly in Japan.
    Hoshi SL; Kondo M; Okubo I
    Vaccine; 2017 May; 35(24):3264-3271. PubMed ID: 28479176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Herpes zoster and postherpetic neuralgia.
    Johnson RW
    Expert Rev Vaccines; 2010 Mar; 9(3 Suppl):21-6. PubMed ID: 20192714
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Public Health Impact and Cost-Effectiveness of Non-live Adjuvanted Recombinant Zoster Vaccine in Canadian Adults.
    McGirr A; Van Oorschot D; Widenmaier R; Stokes M; Ganz ML; Jung H; Varghese L; Curran D
    Appl Health Econ Health Policy; 2019 Oct; 17(5):723-732. PubMed ID: 31250218
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.
    Rothberg MB; Virapongse A; Smith KJ
    Clin Infect Dis; 2007 May; 44(10):1280-8. PubMed ID: 17443464
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 71.